Bladder News and Research

RSS

China Medical receives SFDA approvals for TOP2A and prostate cancer FISH detection kits

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced that it has received approvals for its prostate cancer FISH detection kit and Topoisomerase 2-alpha FISH detection kit from the State Food and Drug Administration of the People's Republic of China.

10 Aug 2011

Allergan receives positive opinion from Irish Medicines Board for BOTOX

Allergan is pleased to announce that BOTOX has received a positive opinion from the Irish Medicines Board for the management of urinary incontinence in adults with neurogenic detrusor overactivity (NDO) resulting from neurogenic bladder due to stable sub-cervical spinal cord injury, or multiple sclerosis.

8 Aug 2011

Bladder cancer patients can benefit from radical cystectomy surgery

Bladder cancer patients who have radical surgery at university hospitals can benefit from excellent local control of the disease, acceptable clinical outcomes and low death rates, according to research in the August issue of the urology journal BJUI.

8 Aug 2011

OncoGenex second quarter revenue increases to $1.9 million

OncoGenex Pharmaceuticals, Inc. today provided an update on current events and activities and announced its second quarter financial results.

5 Aug 2011

Celldex second quarter net loss increases to $10.2 million

Celldex Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2011. Celldex reported a net loss of $10.2 million, or $0.27 per share, for the second quarter of 2011 compared to a net loss of $9.5 million, or $0.30 per share, for the second quarter of 2010.

3 Aug 2011

British scientists find seven new gene variants linked to prostate cancer

Cancer Research UK-funded scientists have taken a further step to identifying men at a greater risk of prostate cancer with the discovery of seven new variants in the human genome that increase the chances of developing the disease. The research is published in Nature Genetics.

3 Aug 2011

Celgene reports second quarter total revenue of $1.18 billion

Celgene Corporation announced non-GAAP net income of $417 million, or non-GAAP diluted earnings per share of $0.89, for the quarter ended June 30, 2011. Non-GAAP net income for the second quarter of 2010 was $323 million, or non-GAAP diluted earnings per share of $0.69.

28 Jul 2011

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced results of operations for the second quarter of 2011.

27 Jul 2011

Watson second quarter net revenue increases 24% to $1.1 billion

Watson Pharmaceuticals, Inc. today reported net revenue of $1.1 billion for the second quarter ended June 30, 2011, an increase of 24 percent when compared to $875.3 million in the second quarter 2010.

26 Jul 2011

C-sections on the rise: One in three mothers opting for procedure

According to the latest study reports, one in three births in the U.S. are now delivered by Caesarean section, which is an all time high and an increasd of 25 percent over seven years.

24 Jul 2011

FDA panel votes against novel diabetes drug citing adverse effects

An advisory panel for the US Food and Drugs Administration voted 9-6 that the FDA should not yet approve dapagliflozin, a new type of diabetes drug that makes the body dump sugar and lose weight. Signals of possible liver damage and of breast and bladder cancer worried the experts.

20 Jul 2011

Aeterna's AEZS-108 final Phase 2 results in endometrial cancer to be presented at ESGO 2011

Aeterna Zentaris Inc. today announced that final Phase 2 results in endometrial cancer on its anticancer compound, AEZS-108, will be presented during a poster session at the upcoming 17th International Meeting of the European Society of Gynaecological Oncology, to be held September 11-14, 2011, at the Milan Convention Center in Milan, Italy.

19 Jul 2011

InterStim Therapy now available for treatment of chronic bowel incontinence

A new procedure is now available for the treatment of chronic bowel incontinence, a disorder impacting the lives of more than 18 million Americans. The treatment, called InterStim Therapy is a minimally invasive procedure which uses electrical impulses to stimulate the sacral nerve and improve muscle function.

19 Jul 2011

Men with early-stage prostate cancer can benefit from short-term ADT, radiation therapy

Short-term hormone therapy given in combination with radiation therapy for men with early-stage prostate cancer increases their chance of living longer and not dying from the disease, compared with that of those who receive the same radiation therapy alone, according to a Radiation Therapy Oncology Group (RTOG) study published in the July 14 issue of the New England Journal of Medicine.

14 Jul 2011

Maintaining general health may help reduce risk for dementia

Improving and maintaining health factors not traditionally associated with dementia, such as denture fit, vision and hearing, may lower a person's risk for developing dementia, according to a new study published in the July 13, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology.

14 Jul 2011

Transvaginal placement of surgical mesh for pelvic organ prolapse may pose greater risk, warns FDA

The U.S. Food and Drug Administration today issued an updated safety communication warning health care providers and patients that surgical placement of mesh through the vagina to repair pelvic organ prolapse may expose patients to greater risk than other surgical options.

14 Jul 2011

Bladder cancer patients rarely receive recommended care: Study

According to a study released this week by UCLA's Jonsson Comprehensive Cancer Center, the overwhelming majority of patients with high-grade non-muscle invasive bladder cancer do not receive the recommended treatment and surveillance, leaving them at higher risk for bladder cancer recurrence, progression, and death.

13 Jul 2011

Sequana Medical's ALFApump System for liver cirrhosis receives CE Mark approval

Sequana Medical announced today that it has received CE Mark approval for the commercial sale of its ALFApump System.

13 Jul 2011

Bladder cancer patients missing out on treatment and followups: Study

A new study released this Monday by UCLA's Jonsson Comprehensive Cancer Center shows a large majority of patients with high-grade non-muscle invasive bladder cancer do not receive the recommended treatment and surveillance, leaving them at higher risk for bladder cancer recurrence, progression, and death.

13 Jul 2011

Men more likely to succumb to cancer

According to a new analysis of 36 different types of tumors and blood cancers that affect both sexes, men are more likely than women to get and die of cancer. The report shows that leukemia and cancers of the colon and rectum, pancreas, and liver killed about one and a half to two times as many men as women in the U.S. over a 30-year period. Lung cancer killed nearly two and a half times as many men during that time. According to the American Cancer Society men have about a 1 in 2 chance of developing cancer at some point in their lives, compared with women, who have a 1 in 3 chance.

13 Jul 2011